Mizoribine treatment of young patients with severe lupus nephritis: A clinicopathologic study by the Tohoku Pediatric Study Group

Nephron - Clinical Practice

Volumn 110, Issue 2, 2008, Pages

  Tanaka, Hiroshi ^a   Oki, Eishin ^a   Tsuruga, Kazushi ^a   Sato, Norihiro ^b   Matsukura, Hiroyoshi ^c   Matsunaga, Akira ^d   Kondo, Yoshiaki ^e   Suzuki, Junzo ^f  

^a HIROSAKI UNIVERSITY   (Japan)

^b ASAHI KASEI PHARMA CORPORATION   (Japan)

^c Saiseikai Toyama Hospital   (Japan)

^d YAMAGATA UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Diffuse proliferative lupus nephritis; Histologic progression; Mizoribine, intermittent oral pulse therapy; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIFFUSE PROLIFERATIVE LUPUS NEPHRITIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; HYPERURICEMIA; INFECTION; KIDNEY BIOPSY; LEUKOPENIA; LIVER DYSFUNCTION; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MORNING DOSAGE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SCHOOL CHILD; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; RETROSPECTIVE STUDIES; RIBONUCLEOSIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 50349102869     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151721     Document Type: Article

References (22)

1. Chan TM, Tse KC, Tang CSO, Lai KN, Li FK: Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005;14:265-272.
2. Lai KN, Tang SCW, Mok CC: Treatment for lupus nephritis: a revisit. Nephrology (Carlton) 2005;10:180-188.
3. Lehman TJ, Onel K: Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000;136:243-247.
4. Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N: Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 2007;16:972-980.
5. Yokota S: Mizoribine: Mode of action and effects in clinical use. Pediatr Int 2002;44:196-198.
6. Tanaka H, Tsugawa K, Tsuruga K, Nakahata T, Suzuki K, Ito E, Waga S: Mizoribine for the treatment of lupus nephritis in children and adolescents. Clin Nephrol 2004;62:412-417.
7. Yumura W, Suganuma K, Uchida K, Moriyama T, Otsubo S, Takei T, Naito M, Koike M, Nitta K, Nihei H: Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol 2005;64:28-34.
8. Sonda K, Takahashi K, Tanabe K, Fuchinoue S, Hayasaka Y, Kawaguchi H, Teraoka S, Toma H, Ota K: Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc 1996;28:3643-3648.
9. Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Ito E, Waga S: Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis. Clin Nephrol 2003;60:390-394.
10. Tanaka H, Tsugawa K, Suzuki K, Nakahata T, Ito E: Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis. Pediatr Nephrol 2006;21:962-966.
11. Tanaka H, Oki Es, Tsugawa K, Suzuki K, Tsuruga K, Ito E: Long-term intermittent pulse therapy with mizoribine attenuates histologic progression in young patients with severe lupus nephritis: report of two patients. Nephrology (Carlton) 2007;12:376-379.
12. Tanaka H, Tsugawa K, Oki E, Suzuki K, Waga S, Ito E: Long-term mizoribine intermittent pulse therapy, but not azathioprine therapy, attenuated histologic progression in a patient with severe lupus nephritis (letter). Clin Nephrol 2007;68:198-200.
13. Tanaka H, Tsugawa K, Oki E, Suzuki K, Ito E: Mizoribine intermittent pulse therapy for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin Rheumatol 2008;27:85-89.
14. Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, Bombardieri S: The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000;9:445-450.
15. Austin HA, Muenz LR, Joyce KM, Antonnovych TT, Balow JE: Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689-695.
16. Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, Wada Y, Murakami S, Hasegawa H, Ito S, Sakatsume M, Nakano M, Gejyo F: Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy. Mod Rheumatol 2007;17:206-212.
17. Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H: Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun 2000;274:87-92.
18. Nozu K, Iijima K, Kamioka I, Fujita T, Yoshiya K, Tanaka R, Nakanishi K, Yoshikawa N, Matsuo M: High-dose mizoribine treatment for adolescents with systemic lupus erythematosus. Pediatr Int 2006;48:152-157.
19. Kamata K, Okubo M, Uchiyama T, Masaki Y, Kobayashi Y, Tanaka T: Effect of mizoribine on lupus nephropathy of New Zealand black/white F1 hybrid mice. Clin Immunol Immunopathol 1984;33:31-38.
20. Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Hyodo N, Suzuki S, Miura S: Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol Dial Transplant 2005;20:1573-1581.
21. Itoh H, Komatsuda A, Wakui H, Miura AB, Tashima Y: Mammalian HSP60 is a major target for an immunosuppressant mizoribine. J Biol Chem 1999;274:35147-35151.
22. Ikezumi Y, Suzuki T, Karasawa T, Kawachi H, Nikolic-Paterson DJ, Uchiyama M: Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy. Pediatr Nephrol 2008;23:645-650.